Ocular inflammatory diseases are major causes of vision loss in the United States, at a relatively early age. Immunosuppression is a primary therapeutic approach for severe cases. In a, a multicenter retrospective cohort study, we linked 7,957 ocular inflammation patients seen by 2005 inclusive to the National Death Index (NDI), finding 936 deaths over 66,902 person-years of follow-up for mortality. Primary findings included: 1) a suggestion of substantially increased overall and cancer mortality with Tumor Necrosis Factor (TNF) inhibitor therapy;2) no increased risk of overall and cancer mortality with antimetabolite, T-cell inhibitor, or systemic corticosteroid therapy;and 3) overall and cancer mortality risk very similar the general population (suggesting that inflammatory eye diseases patients may be a group in which the indications-for- treatment will not bias study of the relationship between treatment use and mortality or cancer). Millions of individuals in the United States use TNF inhibitors for a range of inflammatory diseases. We propose to extend the study for five years in order to: 1) validate preliminary findings re: overall and cancer mortality risk with TNF inhibitor therapy;2) evaluate cancer incidence (fatal and non-fatal) for all four major classes of immunosuppressive agents;3) generalize statistical methodology accounting for time- dependent confounding to the paired organ setting, to allow more valid analyses of treatment effects using observational ophthalmic data;and, 4) apply these methods to evaluate the relative (cost-) effectiveness of alternative immunosuppressive drugs. We will increase the cohort size by ~35% at the five original centers;the follow-up time and number of deaths observed will nearly double. TNF inhibitor-focused enrollment at ancillary centers will enhance statistical power for aim #1. We will link the enlarged database to the NDI and state cancer registries, with a new co-investigator who successfully completed a similar multiple cancer registry study. A biostatistical methodologist will generalize methods for dealing with time-dependent confounding to the paired organ setting, applying these methods along with a seasoned health economist to directly compare the costs and effectiveness of alternative immunosuppresive drugs for ocular inflammation.
The drugs studied are used by millions;well-powered estimates of their impact on mortality and cancer will affect risk-benefit ratios profoundly, widely influencing management of eye and systemic diseases of immunity. Estimation of the relative (cost-)effectiveness of alternative immunosuppressants for ocular inflammation will greatly increase the quality of evidence available to guide rational clinical management.
|Artornsombudh, Pichaporn; Pistilli, Maxwell; Foster, C Stephen et al. (2014) Factors predictive of remission of new-onset anterior uveitis. Ophthalmology 121:778-84|
|Levin, Marc H; Pistilli, Maxwell; Daniel, Ebenezer et al. (2014) Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology 121:588-95.e1|
|Mehta, Sonia; Hariharan, Luxme; Ho, Allen C et al. (2013) Peripapillary choroidal neovascularization in pars planitis. J Ophthalmic Inflamm Infect 3:13|
|Baxter, Sally L; Pistilli, Maxwell; Pujari, Siddharth S et al. (2013) Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol 156:468-77.e2|
|Lerman, Melissa A; Burnham, Jon M; Chang, Peter Y et al. (2013) Response of pediatric uveitis to tumor necrosis factor-* inhibitors. J Rheumatol 40:1394-403|
|Kempen, John H (2011) Appropriate use and reporting of uncontrolled case series in the medical literature. Am J Ophthalmol 151:7-10.e1|
|Kempen, John H (2011) The need for a revised approach to epidemiological monitoring of the prevalence of visual impairment. Ophthalmic Epidemiol 18:99-102|
|Pasadhika, Sirichai; Kempen, John H; Newcomb, Craig W et al. (2009) Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 148:500-509.e2|
|Kempen, John H; Gangaputra, Sapna; Daniel, Ebenezer et al. (2008) Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 146:802-12.e1|
|Kacmaz, R Oktay; Kempen, John H; Newcomb, Craig et al. (2008) Ocular inflammation in Behcet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146:828-36|
Showing the most recent 10 out of 15 publications